Literature DB >> 5103749

The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols.

J A Mahoudeau, C W Bardin, M B Lipsett.   

Abstract

Dihydrotestosterone metabolism was studied with a constant infusion technique in three men, three women, five hirsute women, and four estrogen-treated hirsute women. The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]). The metabolic clearance rates in hirsute patients were intermediate between those men and women and were decreased by estrogen treatment. These observations demonstrate similarities in the metabolic rates of testosterone and dihydrotestosterone. The conversion of plasma testosterone and androstenedione to dihydrotestosterone was studied in men and hirsute women. Approximately 4 and 2% of plasma testosterone and androstenedione, respectively, were converted to plasma dihydrotestosterone in both groups. From these observations it was determined that a major fraction of plasma dihydrotestosterone was derived from these plasma precursors rather than from glandular secretion. Both 5alpha-androstan-3alpha,17beta-diol (3alpha-diol) and 5alpha-androstan-3beta,17beta-diol (3beta-diol) were identified in plasma during dihydrotestosterone and testosterone infusions. The conversion ratio of dihydrotestosterone to 3alpha-diol (C(BB) (DHT-3alpha)) was greater than the conversion ratio to the 3beta-isomer (C(BB) (DTH-3beta)) in all the patients studied. Both C(BB) (DHT-3alpha) and C(BB) (DHT-3beta) were higher in men (mean values of 0.151 [range, 0.110-0.222] and 0..031 [range, 0.022-0.042]) than in women (means of 0.044 [range, 0.037-0.048] and 0.012 [range 0.010-0.013]). A smaller fraction of testosterone was converted to 3alpha-diol and 3beta-diol.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5103749      PMCID: PMC292065          DOI: 10.1172/JCI106613

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Catabolism of [4-14C]testosterone by subcellular fractions of human prostate.

Authors:  J Chamberlain; N Jagarinec; P Ofner
Journal:  Biochem J       Date:  1966-06       Impact factor: 3.857

2.  The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

Authors:  N Bruchovsky; J D Wilson
Journal:  J Biol Chem       Date:  1968-04-25       Impact factor: 5.157

3.  Studies of testosterone binding globulin.

Authors:  T Kato; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1968-08       Impact factor: 5.958

4.  Studies on testosterone metabolism in human subjects with normal and pathological sexual differentiation.

Authors:  P Mauvais-Jarvis; H H Floch; J P Bercovici
Journal:  J Clin Endocrinol Metab       Date:  1968-04       Impact factor: 5.958

5.  Metabolism of testosterone and action of metabolites on prostate glands grown in organ culture.

Authors:  E E Baulieu; I Lasnizki; P Robel
Journal:  Nature       Date:  1968-09-14       Impact factor: 49.962

6.  Studies of androgens in transsexual subjects. Effects of estrogen therapy.

Authors:  C J Migeon; M A Rivarola; M G Forest
Journal:  Johns Hopkins Med J       Date:  1968-09

7.  Further study of factors affecting the metabolic clearance rate of testosterone in man.

Authors:  A L Southren; G G Gordon; S Tochimoto
Journal:  J Clin Endocrinol Metab       Date:  1968-08       Impact factor: 5.958

8.  Effect of the administration of estrogen on the disappearance of 3H-testosterone in the plasma of human subjects.

Authors:  C E Bird; R N Green; A F Clark
Journal:  J Clin Endocrinol Metab       Date:  1969-01       Impact factor: 5.958

9.  Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone.

Authors:  R Horton; J F Tait
Journal:  J Clin Invest       Date:  1966-03       Impact factor: 14.808

10.  Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries.

Authors:  C W Bardin; M B Lipsett
Journal:  J Clin Invest       Date:  1967-05       Impact factor: 14.808

View more
  9 in total

Review 1.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

2.  The transport of 25-hydroxycholecalciferol in a New World monkey.

Authors:  A W Hay
Journal:  Biochem J       Date:  1975-10       Impact factor: 3.857

3.  Male gonadal function in coeliac disease: 2. Sex hormones.

Authors:  M J Farthing; L H Rees; C R Edwards; A M Dawson
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

4.  Interaction of prolactin and testosterone in the human prostate.

Authors:  W E Farnsworth; W R Slaunwhite; M Sharma; F Oseko; J R Brown; M J Gonder; R Cartagena
Journal:  Urol Res       Date:  1981

5.  Steroids after birth-puberty.

Authors:  W A Marshall
Journal:  Postgrad Med J       Date:  1976-10       Impact factor: 2.401

6.  Circulating dihydrotestosterone may not reflect peripheral formation.

Authors:  V Toscano; R Horton
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

7.  Urinary unconjugated 5 alpha-androstane-3 alpha, 17 beta-diol in patients with prostatic tumours.

Authors:  C M Puah; G Williams; R Ghanadian
Journal:  Urol Res       Date:  1982

8.  3Alpha-androstanediol kinetics in man.

Authors:  T Kinouchi; R Horton
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

9.  Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism.

Authors:  J M Saez; M G Forest; A M Morera; J Bertrand
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.